Tocilizumab and Atezolizumab in Adults With Locally Advanced or Metastatic Non-Small Cell Lung Cancer Refractory to 1st Line Immune Checkpoint Inhibitor-Based Therapy

Description

This is a research study to evaluate the safety and effectiveness of tocilizumab in combination with atezolizumab to treat non-small cell lung cancer.

Conditions

Lung Cancer, Nonsmall Cell

Talk to us

Study Overview

On this page

Study Details

Study overview

This is a research study to evaluate the safety and effectiveness of tocilizumab in combination with atezolizumab to treat non-small cell lung cancer.

A Phase Ib-II Trial of Tocilizumab and Atezolizumab in Patients With Locally Advanced or Metastatic Non-Small Cell Lung Cancer Refractory to 1st Line Immune Checkpoint Inhibitor-Based Therapy

Tocilizumab and Atezolizumab in Adults With Locally Advanced or Metastatic Non-Small Cell Lung Cancer Refractory to 1st Line Immune Checkpoint Inhibitor-Based Therapy

Condition
Lung Cancer, Nonsmall Cell
Intervention / Treatment

-

Contacts and Locations

Philadelphia

Abramson Cancer Center of the University of Pennsylvania, Philadelphia, Pennsylvania, United States, 19104

Participation Criteria

Researchers look for people who fit a certain description, called eligibility criteria. Some examples of these criteria are a person's general health condition or prior treatments.

For general information about clinical research, read Learn About Studies.

Eligibility Criteria

  • * Advanced non-squamous NSCLC (Stage IV or recurrent after initial curative intent therapy) in adults age 18 or older
  • * Prior exposure to at least 1 line of therapy
  • * Exposure to a including checkpoint inhibitor in line of therapy immediately prior to enrollment on trial
  • * ECOG PS 0-2
  • * Presence of a driver mutation that is susceptible to targeted therapy
  • * No greater than CTCAE v5 grade 3 toxicity attributed to prior immunotherapy
  • * Other active invasive malignancy requiring ongoing therapy
  • * Evidence of progressing or untreated brain metastases
  • * Evidence or history of leptomeningeal disease
  • * Uncontrolled tumor related pain
  • * History of an autoimmune disease or IPF

Ages Eligible for Study

18 Years to

Sexes Eligible for Study

ALL

Accepts Healthy Volunteers

No

Collaborators and Investigators

Abramson Cancer Center at Penn Medicine,

Melina Marmarelis, MD, MSCE, PRINCIPAL_INVESTIGATOR, Abramson Cancer Center at Penn Medicine

Study Record Dates

2026-09